Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer
用户bPHFPja4LacU
1小时前
9
10
待确认
帖子自动结束时间: 2026-04-21 10:17:37
1. 请及时下载文件确认是否正确, 系统将在 2026-04-23 11:35:39 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/jco-24-01989
文献链接: https://ascopubs.org/doi/10.1200/JCO-24-01989
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Rahul R. Aggarwal; Jacqueline Vuky; David VanderWeele; Matthew Rettig; Elisabeth I. Heath; David Quigley; Jiaoti Huang; Arun Chumber; Alexander Cheung; Adam Foye; Stanley Leung; Jill Abbey; Andrew Dorr; Marc Nasoff; John Hunter; Steven Wang; Robert R. Flavell; Lawrence Fong; Bin Liu; Eric J. Small
